U.S. Markets closed

Exondys 51 Growth Bodes Well for Sarepta’s Top Line

Kenneth Smith
Exondys 51 Growth Bodes Well for Sarepta’s Top Line

Sarepta Therapeutics (SRPT) is a commercial-stage biopharmaceutical company focused on developing unique RNA-targeted therapeutics, gene therapy, and other genetic products targeted for rare neuromuscular diseases. Sarepta’s first product on the market, Exondys 51 (eteplirsen), is indicated for treating Duchenne muscular dystrophy (or DMD). In June, the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a negative opinion for eteplirsen.